VeraSci will be attending CTAD 2020, on November 4-7. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.  We look forward to meeting with you in Boston!